Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas and position it as a dominant utility in a region that’s struggling to meet the surge in demand from newly built artificial intelligence facilities.
- Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. 
- Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker’s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the “disappointing” trial update. 

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - NextEra Energy (NEE) agreed to pay about $67 billion in stock for Dominion Energy (D) in the biggest power acquisition ever, creating a giant utility extending from Florida to the data centers clustered in Virginia. The deal would give NextEra a swathe of electricity assets stretching across Virginia and the Carolinas and position it as a dominant utility in a region that&rsquo;s struggling to meet the surge in demand from newly built artificial intelligence facilities. - Ryanair (RYAAY) gains as it delivered a decent end to the year, but flagged impact ahead from rising costs. The airline said unit costs for 2027 could increase by a mid-single digit percentage, with concerns over current unhedged jet fuel prices, and also impact from higher crew and aircraft maintenance costs. - Regeneron Pharmaceuticals (REGN) shares drop after the drugmaker&rsquo;s phase 3 data for fianlimab in metastatic melanoma fell short of expectations. Citi downgraded its rating on the stock following the &ldquo;disappointing&rdquo; trial update.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. 

Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for five-minute conversations on today's biggest winners and losers in the stock market.&nbsp;
Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

NextEra to Buy Dominion; Ryanair Rallies; Regeneron Drops on Disappointing Data

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/6d70c551-9da1-447b-b3c5-b44e00d9e07b/transcript